Institutional members access full text with Ovid®

Share this article on:

Investigation of Maltose Interference on the Roche ACCU-CHEK Inform II Blood Glucose Meter

Stene, Dawn BS; Song, Lu PhD

Point of Care: The Journal of Near-Patient Testing & Technology: March 2016 - Volume 15 - Issue 1 - p 26–29
doi: 10.1097/POC.0000000000000083
Original Articles

Maltose can interfere with glucose measurement with the Roche (Roche Diagnostics, Indianapolis, Ind) ACCU-CHEK Inform I (Inform-I) blood glucose meter, which utilizes the glucose dehydrogenase pyrroloquinolinequinone methodology and cause falsely elevated glucose results. Maltose can be present in the blood of patients who were treated with peritoneal dialysis using icodextrin or immunoglobulin preparations containing maltose. Roche has developed a new glucose meter ACCU-CHEK Inform II (Inform-II) using a mutant quinone glucose dehydrogenase. In order to study the effect of maltose on the glucose measurement with Inform-I and Inform-II, we prepared samples with known concentration of maltose and measured glucose in these samples. The results exhibited a linear relationship between the amount of falsely elevated glucose result and the concentration of maltose. Our results showed that both the Inform-I and Inform-II exhibited maltose interference, and the amount of falsely elevated glucose result is proportional to the concentration of maltose. However, significant reduction of maltose interference was observed with Inform-II. When maltose concentrations were 240, 360, and 720 mg/dL, the amounts of falsely increased glucose result were only 10, 16, and 34 mg/dL with Inform-II, respectively, in contrast to 151, 225, and 491 mg/dL with Inform-I. When samples from 3 patients who underwent icodextrin peritoneal dialysis were measured with Inform-II, the glucose results were comparable to those obtained with Beckman Coulter AU5400 indicating little or no maltose interference in these samples.

From the *Clinical Laboratory, Ronald Reagan Hospital, UCLA Medical Center; and †Department of Pathology and Laboratory Medicine, David Geffen School of Medicine UCLA, Los Angeles, CA.

Reprints: Lu Song, PhD, Department of Pathology and Laboratory Medicine, B403L, Ronald Reagan Hospital, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095. E-mail: lusong@mednet.ucla.edu.

All authors are salaried employees of University of California. No external funding was received for this study.

Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved